CancerFree Biotech Ltd.

CancerFree Biotech aspires to help doctors develop optimal cancer treatment strategies that minimize patient pain and inefficient drug use.

2019/10
Selected into AZ-NBRP International Accelerator
2020/05
Received SBIR Grant
2020/08
Selected in SmartLabs Accelerator
2020/11
Won the First Prize of China Innovation Entrepreneurship
2021/04
Joined Berkeley SkyDeck Cohort program
2021/12
Taiwan 18th National Innovation Award
Up to now, we have completed more than 800 clinical cases, including over 100 paid cases. Our service is applicable to 134 types of cancer and 100 generic drugs are also available for screening. The early clinical data shows the average clinical response rate is 76.9%.

Today, one of the main causes behind the deadly nature of cancer is low therapeutic efficacy. Many cancer patients suffer greatly from the side effects of anti-cancer drugs and simply do not have the strength or time to try different treatments in hopes of finding the most optimal strategy. Additionally, with traditional drug testing, solid tumors are required to be obtained from surgery or puncture, but this is not suitable for every cancer patient.

We are the first to commercialize an in vitro tumor cell culture platform from low-risk liquid biopsies. Through our platform E.V.A. (Ex-Vivo Avatar) Select, physicians can see the actual effects of different drugs on patients cancer cells and can tailor personalized treatments to their conditions, reducing the risk and cost of potentially ineffective drugs.

• B2B Drug Discovery: Provide patient-derived tumor cells to new cancer drug development companies to validate the drug suppression effect on tumor cells from real patients.
• B2B2C Drug Selection: Provide services to patients through hospital or distributor channels. Helping doctors develop the optimal treatment strategy for cancer patients and reducing the chance of ineffective drug use.
• Our B2B2C current distributers: JW diagnostic Inc., Phalanx Biotech Group Inc.
• Our B2B current customer: Grape King Bio., Unimed Healthcare Inc.

Berkeley Skydeck Cohort Program
TAcc+ Propel
Smartlabs
AstraZeneca-NBRP International Accelerator